Sign up
Pharma Capital
Why invest in CPT?

Concepta PLC raises £2mln in oversubscribed share placing and confirms key Chinese order has been placed

The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development
couple looking at pregnancy test
The company’s key product is myLotus, an easy-to-use home test that has been developed for women who have been trying to conceive for six months or more

Fertility specialist Concepta plc (LON:CPT) said it had conditionally raised £2mln in an over-subscribed share placing and announced the formal sign-off on a £600,000 Chinese deal.

The stock was sold at 7p – a modest discount to Friday’s close – and the proceeds will be used to fund its expansion in the People’s Republic, though some of the cash will be invested in new product development.

READ: Concepta expects 'transformational' 2018 as it tackles supply chain issues

WATCH; Concepta chief on Chinese deals 

Announced last Monday (Nov 6), the order for 5,200 myLotus fertility meters by the ShanDong WeiHai HaiChen Pharmaceutical Co has now been placed, with revenues from the deal expected to fall onto the top-line by the end of the year.

“We expect to be able to announce further orders in the coming months and I look forward to updating shareholders in due course," said chief executive Eric Henau.

In a separate announcement, its third of the morning, Concepta said it had appointed Novum Securities joint broker to work alongside Beaufort Securities.

Main product

The company’s key product is myLotus, an easy-to-use home test that has been developed for women who have been trying to conceive for six months or more.

It measures hormone levels in urine to give quantitative and qualitative measurements that might help explain the apparent lack of fertility.

Competitor products currently only allow qualitative measurement and are based on the 'average woman'.

On sale now in China, the commercial launch for myLotus in Germany and the UK is expected in the first half of next year, once the company has received regulatory sign-off in the form of a CE mark.

Stress tests the next development

Concepta has more than just myLotus in its armoury, though; it’s currently working on a stress test to help both women and men with fertility problems.

A technology transfer and licence agreement has been agreed with Selective Antibodies, a UK based diagnostics company.

Concepta will be given exclusive rights to rights to Selective’s intellectual property in return for fees and a royalty on any products sold.

At present, the Lotus platform capabilities include measurements of a woman's personal hCG and LH hormone levels.

With Selective’s input, Concepta wants to expand this reach to quantitative measurement of stress hormones such as cortisol. 


Register here to be notified of future CPT Company articles
View full CPT profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.